All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-07-28T14:29:21.000Z

How to provide better supportive care

Jul 28, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

Bookmark this article

During a meeting of the AML Hub Steering Committee on June 1, 2022, Gail Roboz, Weill Cornell Medicine, New York, US, chaired a discussion session on the topic of “How to provide better supportive care”, which was identified as an unmet educational need within AML treatment.

Roboz starts by introducing “supportive care” as a subject that is often overlooked when presenting information to clinicians and patients, and then invites the committee to comment on the prophylaxis of infectious diseases in their own clinical practice. The committee then offers recommendations for coping with diagnosis and intensive chemotherapy, exploring subjects such as the evolving literature on this topic, and the patient’s need for continuity. Finally, they cover the diet in patients with AML, and Uwe Platzbecker concludes by highlighting the impact that excessive use of prophylactic supplementation can have on the microbiome and recommending careful selection within treatment plans.

How to provide better supportive care

 

More about...

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 2 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox